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Aims: Hypercholesterolemia coexisting with diabetes still requires clinical intervention to manage the high risk of
cardiovascular disease it poses. No second-step strategy is established, however, for cases where strong statins fail
to bring cholesterol down to target levels. In this study we seek to demonstrate the superior effect of ezetimibe
in combination with strong statins to reduce LDL-C in Japanese patients suffering from both T2DM and hyper
LDL-cholesterolemia.
Methods: T2DM outpatients (109 patients from 16 institutes) who failed to achieve the target LDL-C value were
recruited and randomly assigned to two groups, a double-dose-statin group and ezetimibe-plus-statin group.
Follow-ups were scheduled at 0, 12, 26, and 52 weeks. The primary endpoint was the percentage change in the
level of LDL-C from baseline to 12 weeks.
Interim results: We could successfully create randomized (gender, age, LDL-C, HbA1c, etc.) two groups except for
slight differences in apolipoprotein-B and sd-LDL.
Conclusions: RESEARCH is the first prospective, parallel-group, multicenter study comparing a double dose of
strong statin with ezetimibe plus strong statin for T2DM patients. The RESEARCH study will provide reliable
evidence with which to establish a clinical strategy for diabetics who fail to achieve the target LDL-C value.
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Table 1 Entry and exclusion criteria
Entry criteria
Japanesess
Type 2 diabetes mellitus
Age≥ 20 years
Using atorvastatin 10 mg/day or pitavastatin 1 mg/day for > 1 month
LDL-C≥ 120 mg/dL for patients without CAD , LDL-C≥ 100 mg/dL
for patients with CAD
Exclusion criteria
Pregnant, possible to become pregnant, or brest-feeding to baby(s)
Hypersensitive to the medicines concerned
Liver dysfunction
HbA1C≥ 9.4%
Serum creatinine≥ 2.0 mg/dL
Triglyceride≥ 400 mg/dL
Secondary dyslipidemia, drug-induced dyslipidemia
Homozygotic familial hypercholesterolemia
Other non-specific reason, such as poor adherence
CAD: coronary artery disease.
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The incidence of metabolic disease, a condition often as-
sociated with coronary artery disease (CAD) or stroke is
increasing substantially all over the world. According to a
Japanese government publication from 2010, some 17.4
million cases of diagnosed or suspected diabetes were
reported in the country, about 31.4% more than the num-
ber reported in the earlier surveillance from 2002 [1].
Among them, patients with diabetes mellitus face a strong
risk of both CAD and stroke. JDCS [2], a cohort study of
Japanese type 2 (T2) diabetics, reported a CAD incidence
of 9.6/1,000 T2DM patients/year and a stroke incidence of
7.5/1,000 T2DM patients/year. The Hisayama Study [3],
another Japanese cohort study, respectively showed CAD
and stroke incidences of 8.0 and 10.2 /1000 persons/year
in type 2 diabetic patients, versus incidences of 3.4 and
4.0/1,000 persons/year in subjects with normal glucose
tolerance. According to those data, Japanese diabetics
were exposed to a two-fold higher risk of cardiovascular
disease than subjects with normal glucose tolerance.
The risk of cardiovascular disease in diabetes mellitus
is pushed sharply higher by hypercholesterolemia,
especially elevated low-density lipoprotein cholesterol
(LDL-C). Apart from dietary and lifestyle intervention,
hydroxylmethylglutarylcoenzyme-A -reductase -inhibitors
(statins) have been the primary component of LDL-C-low-
ering therapy. The MEGA study [4], a randomized con-
trolled trial from Japan, has shown that LDL-C reduction
by pravastatin reduces the incidences of CAD and stroke
in Japanese subjects, effectively duplicating the results
from larger trials with global populations [5-8]. Patients
who fail to achieve the LDL-C target with a regular dose
of strong statins have the option of increasing the statin
dose or combining the statins with other classes of
lipid-lowering medications such as ezetimibe, bile acid
sequestrans, fibrates, niacins, or ω3-fatty acids. Ezetimibe,
a cholesterol absorption inhibitor, targets the cholesterol
transporter protein Niemann Pick C1 like 1 at the jejunal
enterocyte brush border and localizes there to inhibit the
absorption of cholesterol from the gastrointestinal and
biliary systems [9-11]. Ezetimibe administered in com-
bination with statin reduces LDL cholesterol levels and
the incidences of the following major atherosclerotic
events: nonfatal myocardial infarction, coronary death,
nonhemorrhagic stroke, and revascularization proce-
dures in CKD [12]. In this study we seek to demonstrate
the superior effect of ezetimibe-plus-strong-statin in re-
ducing LDL-C levels in Japanese patients suffering from
both type 2 diabetes mellitus (T2DM) and hyper LDL
cholesterolemia.
Methods/design
The RESEARCH study is a prospective, randomized, parallel-
group, active-controlled, doctor-oriented, multicenter, clinicaltrial designed to examine whether ezetimibe combined
with a regular dose of strong statin significantly lowers the
serum LDL-C concentration in Japanese T2DM patients,
compared with a double dose of strong statin adminis-
tered without ezetimibe.
The study is conducted and managed with the ap-
proval of the ethics committee at each institute and con-
forms closely with the Declaration of Helsinki and the
guidelines from the Japanese Ministry of Health, Labor
and Welfare (complete revision on December 28, 2004).
The protocol has been registered in the UMIN Clinical
Trials Registry (UMIN000002593) [13].Patients
Entry criteria and exclusion criteria are shown in Table 1.
The patients enrolled in this study were T2DM outpatients
who had failed to achieve the LDL-C target recommended
by the Japanese guideline, namely, LDL-C < 120 mg/dL for
patients without CAD or LDL-C < 100 mg/dL for patients
with CAD [14], in spite of receiving strong statin treatment
at the standard dose according to Japan’s national health
insurance policy (10 mg/day of atorvastatin or 1 mg/day of
pitavastatin). Changes in LDL-C values were examined
using Friedewald’s formula, so patients with hypertriglyc-
eridemia of over 400 mg/dL had to be excluded.
Patients who provided informed consent were ran-
domly assigned to two groups, a double-dose-statin (DS)
group and ezetimibe-plus-statin (ES) group. The patients
were randomized through a system for online central
registration. To reduce heterogeneity between groups,
dynamic allocation was adopted using age and gender as
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were open to both the patients and doctors.
Treatments and data collection (Figure 1)
The patients assigned to the DS group are given double
the basal dose of statin. The patients assigned to the ES
group are given the basal dose of statin in combination
with 10 mg/day of ezetimibe. Data are collected at 0, 12,
26, and 52 weeks. After 12 weeks of treatment, a higher
dose of statin is allowed, when necessary, in the ES group,
and a higher dose of either statin or ezetimibe is allowed,
when necessary, in the DS group. The patients receive
none of the following agents during the study: statins
other than atorvastatin or pitavastatin, anion-exchanging
resin agents, fibrates, nicotinic acids, eicosapentaenoic
acid, probucol, and other lipid-lowering agents.
End points
The primary endpoint is the percentage change in the
level of serum LDL-C from baseline to week 12 of treat-
ment. Along with the LDL-C decrements, percentage of
patients who reached the treatment goals (LDL-C
<120 mg/dl or <100 mg/dl) was placed at one of the sec-
ondary endpoints. Another major secondary endpoint is
the effects to the particle size of LDL, whereby measured
by amount of small dense low-density lipoprotein
(sd-LDL) or remnant-like particle cholesterol (RLP-C).
The other secondary endpoints are the high-densityrandomiz
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Figure 1 Design scheme for the RESEARCH study. The numbers of patilipoprotein cholesterol (HDL-C), total cholesterol (TC),
triglyceride (TG), high sensitivity C-reactive protein
(HS-CRP), and HbA1c, as well as the rate at which the
subjects achieve the LDL-C target recommended under
the Japanese guideline.
Whereas the effect of the modification will be ob-
served about the patients to whom treatment changes
will be applied by not achieving the target level during
the extended periods after 12 weeks, long term effects of
the regimen of each group will be evaluated as to the
subjects without treatment modification in the same
period.
Data measurement
Samples for sd-LDL are collected at Professor Tsutomu
Hirano’s laboratory (Showa University, Tokyo, Japan)
and measured by his precipitation method [15]. Samples
for RLP-C and HS-CRP are collected and measured in a
single laboratory (SRL Inc. Tokyo, Japan). LDL-C values
are determined with the Friedelwald’s formula (LDL-C =
TC – HDL-C – TG/5). Non-HDL-C values are calcu-
lated as TC – HDL-C. The measurements for TC, HDL-
C, and TG and routine laboratory tests for parameters
such as HbA1C, glucose, AST, ALT, and CK are
performed at the participating institutes. Malondial-
dehyde modified LDL (MDA-LDL) is measured only for
patients with CAD, in order to stay within the restric-










ents appear inside brackets. T2DM: type 2 diabetes mellitus.
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The contributors to this study are listed in Table 2. The
chair investigator is Professor Teruo Shiba at Toho
University Ohashi Medical Center. Study coordination
and monitoring are consigned to Nouvelle Plus Co., Ltd.
of Tokyo, Japan.
Statistical design and analysis
Under the current assumptions, 60 patients need to be en-
rolled in each group. This number is estimated from the
following hypothesis: a doubled statin dose leads to a
11.7% reduction in LDL-C, whereas the addition of
ezetimibe leads to a 21.7% reduction in LDL-C (standard
deviation: 15%). The significance level is set at 5%, power is
set to 90%, and the follow-up ratio is estimated to be 80%.
About the end points, differences between the two
groups for categorical variables will be assessed using
the χ2-test, and continuous variables will be evaluated
using the Wilcoxon test. The Wilcoxon signed-rank test
will be used to assess the difference in parameters before
and after treatment within each group. Significance is
set at a p value of less than 0.05 (2-sided) in all analyses.
All data will be analyzed using Stata® version 12.1
(StataCorp LP., Texas, USA).
Interim results
Informed consent was obtained from 119 patients at 16
institutes in Japan over the period from July 2009 to


















Yasumichi Mori2 years, but extended to 3 years based on the progress of
subject registration. After excluding 10 patients who
ceased to conform with the entry criteria or who can-
celed their consent, 109 patients were randomly assigned
to two treatment groups: the DS group (n = 56) and the
ES group (n = 53).
The profile of basal treatment was as follows: none
(n = 24), oral treatment (n = 58), injection treatment (n =
27) including single treatment of insulin (n = 9) and
GLP-1 receptor agonist (n = 2). Totally 74 patients was
taking some sort of oral Antidiabetic agents. The num-
ber of patients taking each class of agents was 19 for
thiazolidinedione (TZD), 36 for sulfonylurea (SU), 40 for
biguanide (BG), 21 for α-glucosidase inhibitor (α-GI), 26 for
dipeptidyl peptidase IV (DPP-4) inhibitors, and 7 for glinides.
There were no significant differences between the two
groups in gender or in the percentages of subjects with a
smoking habit, hypertension, hypertriglyceridemia, hypo-
HDL-cholesterolemia, chronic kidney disease, history of
stroke, history of CAD, or family history of CAD (Table 3).
Likewise, there were no significant differences between the
groups in age or the levels of TC, TG, HDL-C, LDL-C,
non-HDL-C, RLP-C, MDA-LDL, apolipoprotein (apo)-A1,
apo-E, fasting glucose, fasting insulin, ALT, AST, γ-GTP,
CK, creatinine, HbA1C, or HS-CRP. There were signifi-
cant but slight differences between the groups in the
values of apo-B and sd-LDL (Table 4). We think the
randomization was quite successful. As the participant in-
stitutes mainly engage in outpatient care for diabetes,Institute
Toho University Ohashi Medical Center
Mitsui Memorial Hospital
Kagawa Nutrition University, Nutrition Clinic
Showa University School of Medicine
The University of Tokyo Hospital
Tokyo Teishin Hospital
Graduate School of Medicine, The University of Tokyo
Kashiwa City Hospital
Sanraku Hospital, Life-style related Disease Clinic
Yokohama Rosai Hospital
Tokyo Metropolitan Tama Medical Center
Yokohama City Minato Red Cross Hospital
Toshima Hospital
Japanese Red Cross Medical Center




Table 3 Patient backgrounds, categorical variables
Number of cases Double dose of statin Statin + ezetimibe p
valuen = 56 n = 53
Male % 57.1 58.5 0.887
Smoking % 23.6 25.0 0.869
Family history of CAD % 9.3 9.6 0.950
Hypertension % 67.9 58.5 0.311
Hypertriglyceridemia % 34.5 41.5 0.456
CKD % 16.1 9.4 0.301
Low HDL-C % 3.6 7.5 0.363
History of stroke % 3.6 0.0 0.169
History of CAD % 10.7 15.1 0.495
The data were assessed using the χ2-test. CAD: coronary artery disease.
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rather rare. The HbA1c value (7.20% in total) was not
excellent, but slightly better than that in JDCS [2].
Discussion
When a patient on statins fails to attain good control of
LDL-C, a doubling of the statin dose or the addition ofTable 4 Baseline data on the patients, continuous
variables
Double dose of statin Statin + ezetimibe p
valuemean ± sd n mean ± sd n
age 62.6 ± 9.5 56 61.7 ± 11.1 53 0.4949
TC 218.2 ± 27.2 56 212.5 ± 30.1 53 0.3567
TG 161.9 ± 88.3 56 146.7 ± 95.2 53 0.1803
HDL-C 54.7 ± 9.6 56 56.7 ± 15.2 53 0.9734
LDL-C 135.2 ± 22.6 56 130.6 ± 19.2 53 0.5463
non HDL-C 163.6 ± 25.7 56 155.9 ± 26.9 52 0.1133
RLP-C 6.3 ± 3.9 56 6.1 ± 4.8 52 0.4756
apo A1 146.6 ± 16.6 44 144.2 ± 19.2 40 0.3288
apo B 111.4 ± 18.2 44 101.8 ± 16.5 40 0.0152
apo E 4.1 ± 0.9 44 3.8 ± 1.0 40 0.1604
MDA-LDL 157.0 ± 62.0 12 112.6 ± 27.7 9 0.0549
sd-LDL 52.2 ± 17.9 56 46.2 ± 16.0 52 0.0484
Fasting glucose 132.7 ± 32.5 56 141.5 ± 33.1 53 0.1108
Fasting insulin 10.9 ± 7.0 35 13.8 ± 12.5 28 0.5381
ALT 23.6 ± 10.9 56 24.7 ± 12.5 53 0.8318
AST 23.1 ± 12.1 52 23.7 ± 12.2 49 0.8541
γ-GTP 30.2 ± 21.7 53 28.6 ± 26.6 47 0.3248
CK 116.7 ± 58.2 54 122.5 ± 88.3 51 0.9642
Creatinine 0.81 ± 0.28 56 0.79 ± 0.24 51 0.9627
HbA1C 7.15 ± 1.32 56 7.25 ± 0.64 53 0.6294
hs-CRP 1114 ± 1493 56 922 ± 1119 51 0.6025
The data were evaluated using the Wilcoxon test.ezetimibe seems to be strong choice for general practi-
tioners. Compared to statins alone, the co-administration
of ezetimibe with statins has previously been shown to
produce significant incremental reductions in the plasma
levels of LDL-C in the general population [16-19]. Since
diabetics with hyper-LDL-cholesterolemia are shown to be
at high risk for CV events [20] and only around half of
diabetic patients meet the LDL-C goal both in the U.S.
[21] and in Japan [22], we focused on T2DM patients who
were unable to attain the target LDL-C values proposed
under the Japanese guideline even when receiving regular
doses of strong statins in accordance with the recommen-
dations under Japan’s national health insurance policy. We
are thus comparing the LDL-C-lowering effect of a double
dose of a strong statin and a regular dose of a strong statin
plus ezetimibe in diabetic patients.
Simultaneously, we focus on the particle size changes
of LDL-C that may reflect the difference in the mecha-
nisms of these agents which reduce amount of LDL-C.
Especially, small-dense low-density lipoprotein (sd-LDL)
is recently recognized to be an independent cardiovascu-
lar risk marker, presenting as the change in LDL particle
size. We evaluated the difference of these two treatments
via the major secondary endpoint.
Two earlier reports have compared the effects of co-
administration of ezetimibe with a high dose of a stan-
dard statin (20 mg of simvastatin plus 10 mg of
ezetimibe) with the effects of a double dose of a pre-
scribed standard statin (40 mg of simvastatin in T2DM
patients who had been treated with 20 mg of simva-
statin). In both of these studies, the mean percent reduc-
tions in LDL-C from baseline were significantly greater
in the ezetimibe-plus-simvastatin group than in the
double-dose simvastatin group [23,24]. In RESEARCH
we are looking at the effect of add-on ezetimibe with a
strong statin compared to the effect of a double dose of
a strong statin. We are also looking at ethnic differences
among diabetic patients to analyze whether differences
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fluence the atherogenic properties of serum lipid pro-
files. The clinical backgrounds of the diabetic patients in
the earlier studies have also differed. One study followed
diabetic patients treated with thiazolidinediones [23],
while the other enrolled only diabetic patients with a
history of CAD [25]. Another study compared 80 mg of
atorvastatin versus 40 mg of atorvastatin plus 10 mg of
ezetimibe in T2DM patients who had been treated with
40 mg of atorvastatin alone [25]. In that study, the mean
percent reduction in LDL-C from baseline after 6 weeks
of treatment was greater in the atorvastatin-plus-
ezetimibe group (27%) than in the double-atorvastatin
group (10%). Like us they used a strong statin, but
unlike us they used atorvastatin, administered at super-
high doses, and enrolled patients of variable races.
Additionally, their patients were T2DM, metabolic syn-
drome without T2DM, or subjects with neither meta-
bolic syndrome nor T2DM, hence their analysis on
T2DM was post hoc and insufficient to show statistical
significance. Our study is prospective and our targets are
exclusively T2DM patients on a regular course of strong
statins who nonetheless have failed to achieve the LDL-C
target recommended under the Japanese guideline. It
remains to be seen whether a double dose of strong
statins in those patients is more effective than a regular
dose of strong statins with ezetimibe, or vice versa. Few
reports have addressed this controversial issue, especially
in Japan. According to a single center, crossover study
from Japan on type-2 diabetes patients or IGT (impaired
glucose tolerance) with CAD, co-administration of ezetimibe
was superior to a double dose of strong atorvastatin [26].
Yet in another report from Japan described in Japanese
literature, treatment with ezetimibe plus pitavastatin
brought about more or less the same LDL-C reduction as
a double dose of pitavastatin.
We can reasonably hypothesize that a dual therapy of
ezetimibe and statins has an edge in lowering LDL-C in
T2DM patients, given that these agents affect serum
LDL-C level through different mechanisms, one via re-
duction of intestinal cholesterol absorption, the other via
a mighty inhibition of hepatic cholesterol synthesis. It
would also be of clinical value to assess how the co-
administration of ezetimibe with statins affects the
atherogenic lipid profile in diabetic patients. None of the
abovementioned studies assessed the effect on sd-LDL, a
strong risk factor for CAD [15,27], or on RLP-C, an
independent cardiovascular disease risk factor [28].
Ezetimibe therapy is reported to reduce RLP-C in
Japanese patients with hyper-LDL-cholesterolemia [29].
Ezetimibe affects the size of LDL particles and reduces
the concentration of sd-LDL in T2DM patients [30].
Studies comparing the effects of these two treatments
collaterally on the apolipoproteins revealed no differencesin the effects on apo A1, apo C3, or apo E, whereas
co-administration of ezetimibe with statins signifi-
cantly decreased apo B, the apo found in non-HDL
lipoproteins [19,25].
Our study will be the first prospective, parallel-group,
multicenter comparison between a double dose of a
strong statin and the combination of ezetimibe plus a
strong statin for T2DM patients in actual outpatient
clinics (i.e., patients receiving various treatments for
glycemic control) who take strong statins but nonethe-
less fail to achieve the LDL-C target recommended
under the Japanese guideline. The patients receiving
ezetimibe–plus-statin regimen are expected to show sig-
nificant reductions in the levels of LDL-C, Non-HDL-C,
sd-LDL, and apo-B, and to achieve the LDL-C target
recommended under the guideline at a high rate. The
RESEARCH study is a necessary step to collect reliable
evidence for diabetologists, cardiologists, and general
practitioners.
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